Search

Your search keyword '"Stoot, J. E. G. M."' showing total 8 results
Start Over Author "Stoot, J. E. G. M."
8 results on '"Stoot, J. E. G. M."'

1. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

Author

Aapro, M. S., van Wijk, F. H., Bolis, G., Chevallier, B., van der Burg, M. E. L., Poveda, A., de Oliveira, C. F., Tumolo, S., Scotto di Palumbo, V., Piccart, M., Franchi, M., Zanaboni, F., Lacave, A. J., Fontanelli, R., Favalli, G., Zola, P., Guastalla, J. P., Rosso, R., Marth, C., Nooij, M., Presti, M., Scarabelli, C., Splinter, T. A. W., Ploch, E., Beex, L. V. A., ten Bokkel Huinink, W., Forni, M., Melpignano, M., Blake, P., Kerbrat, P., Mendiola, C., Cervantes, A., Goupil, A., Harper, P. G., Madronal, C., Namer, M., Scarfone, G., Stoot, J. E. G. M., Teodorovic, I., Coens, C., Vergote, I., and Vermorken, J. B.

Published
2003

2. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

Author

Aapro, M. S., van Wijk, F. H., Bolis, G., Chevallier, B., van der Burg, M. E. L., Poveda, A., de Oliveira, C. F., Tumolo, S., Scotto di Palumbo, V., Piccart, M., Franchi, M., Zanaboni, F., Lacave, A. J., Fontanelli, R., Favalli, G., Zola, P., Guastalla, J. P., Rosso, R., Marth, C., Nooij, M., Presti, M., Scarabelli, C., Splinter, T. A. W., Ploch, E., Beex, L. V. A., ten Bokkel Huinink, W., Forni, M., Melpignano, M., Blake, P., Kerbrat, P., Mendiola, C., Cervantes, A., Goupil, A., Harper, P. G., Madronal, C., Namer, M., Scarfone, G., Stoot, J. E. G. M., Teodorovic, I., Coens, C., Vergote, I., Vermorken, J. B., Aapro, M. S., van Wijk, F. H., Bolis, G., Chevallier, B., van der Burg, M. E. L., Poveda, A., de Oliveira, C. F., Tumolo, S., Scotto di Palumbo, V., Piccart, M., Franchi, M., Zanaboni, F., Lacave, A. J., Fontanelli, R., Favalli, G., Zola, P., Guastalla, J. P., Rosso, R., Marth, C., Nooij, M., Presti, M., Scarabelli, C., Splinter, T. A. W., Ploch, E., Beex, L. V. A., ten Bokkel Huinink, W., Forni, M., Melpignano, M., Blake, P., Kerbrat, P., Mendiola, C., Cervantes, A., Goupil, A., Harper, P. G., Madronal, C., Namer, M., Scarfone, G., Stoot, J. E. G. M., Teodorovic, I., Coens, C., Vergote, I., and Vermorken, J. B.

Abstract

Background: Combination chemotherapy yields better response rates which do not always lead to a survival advantage. The aim of this study was to investigate whether the reported differences in the efficacy and toxicity of monotherapy with doxorubicin (DOX) versus combination therapy with cisplatin (CDDP) in endometrial adenocarcinoma lead to significant advantage in favour of the combination. Patients and methods: Eligible patients had histologically-proven advanced and/or recurrent endometrial adenocarcinoma and were chemo-naïve. Treatment consisted of either DOX 60 mg/m2 alone or CDDP 50 mg/m2 added to DOX 60 mg/m2, every 4 weeks. Results: A total of 177 patients were entered and median follow-up is 7.1 years. The combination DOX-CDDP was more toxic than DOX alone. Haematological toxicity consisted mainly of white blood cell toxicity grade 3 and 4 (55% versus 30%). Non-haematological toxicity consisted mainly of grade 3 and 4 alopecia (72% versus 65%) and nausea/vomiting (36 % versus 12%). The combination DOX-CDDP provided a significantly higher response rate than single agent DOX (P <0.001). Thirty-nine patients (43%) responded on DOX-CDDP [13 complete responses (CRs) and 26 partial responses (PRs)], versus 15 patients (17%) on DOX alone (8 CR and 7 PR). The median overall survival (OS) was 9 months in the DOX-CDDP arm versus 7 months in the DOX alone arm (Wilcoxon P = 0.0654). Regression analysis showed that WHO performance status was statistically significant as a prognostic factor for survival, and stratifying for this factor, treatment effect reaches significance (hazard ratio = 1.46, 95% confidence interval 1.05-2.03, P = 0.024). Conclusions: In comparison to single agent DOX, the combination of DOX-CDDP results in higher but acceptable toxicity. The response rate produced is significantly higher, and a modest survival benefit is achieved with this combination regimen, especially in patients with a good performance status

Published
2017

3. Doxurubicin versus doxorubicin and cisplatin in endometrial carcinoma: Definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

Author

Aapro, Matti, van Wijk, F H, Bolis, G, Chevallier, Bernard, van der Burg, Maria, Poveda, Andrés, de Oliveira, Carlos Freire, Tumolo, Salvatore, Scotto di Palumbo, V, Piccart-Gebhart, Martine, Franchi, M, Zanaboni, Flavia, Lacave, Ángel Jiménez, Fontanelli, Rosanna, Favalli, Giuseppe, Zola, Paolo, Guastalla, Jean Paul, Rosso, Riccardo, Marth, C, Nooij, Marianne, Presti, Mauro, Scarabelli, Claudio, Splinter, Ted, Plöchl, Elzbieta, Beex, Louk, ten Bokkel Huinink, Wim, Forni, Mario, Melpignano, Mauro, Blake, Peter, Kerbrat, Pierre, Mendiola, César, Cervantes, Andrés, Goupil, A, Harper, Peter, Madronal, Catherina, Namer, Moïse, Scarfone, G, Stoot, J. E G M, Teodorovic, Ivana, Coens, Corneel, Vergote, Ignace, Vermorken, Jan Baptist, Aapro, Matti, van Wijk, F H, Bolis, G, Chevallier, Bernard, van der Burg, Maria, Poveda, Andrés, de Oliveira, Carlos Freire, Tumolo, Salvatore, Scotto di Palumbo, V, Piccart-Gebhart, Martine, Franchi, M, Zanaboni, Flavia, Lacave, Ángel Jiménez, Fontanelli, Rosanna, Favalli, Giuseppe, Zola, Paolo, Guastalla, Jean Paul, Rosso, Riccardo, Marth, C, Nooij, Marianne, Presti, Mauro, Scarabelli, Claudio, Splinter, Ted, Plöchl, Elzbieta, Beex, Louk, ten Bokkel Huinink, Wim, Forni, Mario, Melpignano, Mauro, Blake, Peter, Kerbrat, Pierre, Mendiola, César, Cervantes, Andrés, Goupil, A, Harper, Peter, Madronal, Catherina, Namer, Moïse, Scarfone, G, Stoot, J. E G M, Teodorovic, Ivana, Coens, Corneel, Vergote, Ignace, and Vermorken, Jan Baptist

Abstract

SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2003

6. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

Author

Aapro, M. S., van Wijk, F. H., Bolis, G., Chevallier, B., van der Burg, M. E. L., Poveda, A., de Oliveira, C. F., Tumolo, S., Scotto di Palumbo, V., Piccart, M., Franchi, M., Zanaboni, F., Lacave, A. J., Fontanelli, R., Favalli, G., Zola, P., Guastalla, J. P., Rosso, R., Marth, C., Nooij, M., Presti, M., Scarabelli, C., Splinter, T. A. W., Ploch, E., Beex, L. V. A., ten Bokkel Huinink, W., Forni, M., Melpignano, M., Blake, P., Kerbrat, P., Mendiola, C., Cervantes, A., Goupil, A., Harper, P. G., Madronal, C., Namer, M., Scarfone, G., Stoot, J. E. G. M., Teodorovic, I., Coens, C., Vergote, I., Vermorken, J. B., Aapro, M. S., van Wijk, F. H., Bolis, G., Chevallier, B., van der Burg, M. E. L., Poveda, A., de Oliveira, C. F., Tumolo, S., Scotto di Palumbo, V., Piccart, M., Franchi, M., Zanaboni, F., Lacave, A. J., Fontanelli, R., Favalli, G., Zola, P., Guastalla, J. P., Rosso, R., Marth, C., Nooij, M., Presti, M., Scarabelli, C., Splinter, T. A. W., Ploch, E., Beex, L. V. A., ten Bokkel Huinink, W., Forni, M., Melpignano, M., Blake, P., Kerbrat, P., Mendiola, C., Cervantes, A., Goupil, A., Harper, P. G., Madronal, C., Namer, M., Scarfone, G., Stoot, J. E. G. M., Teodorovic, I., Coens, C., Vergote, I., and Vermorken, J. B.

Abstract

Background: Combination chemotherapy yields better response rates which do not always lead to a survival advantage. The aim of this study was to investigate whether the reported differences in the efficacy and toxicity of monotherapy with doxorubicin (DOX) versus combination therapy with cisplatin (CDDP) in endometrial adenocarcinoma lead to significant advantage in favour of the combination. Patients and methods: Eligible patients had histologically-proven advanced and/or recurrent endometrial adenocarcinoma and were chemo-naïve. Treatment consisted of either DOX 60 mg/m2 alone or CDDP 50 mg/m2 added to DOX 60 mg/m2, every 4 weeks. Results: A total of 177 patients were entered and median follow-up is 7.1 years. The combination DOX-CDDP was more toxic than DOX alone. Haematological toxicity consisted mainly of white blood cell toxicity grade 3 and 4 (55% versus 30%). Non-haematological toxicity consisted mainly of grade 3 and 4 alopecia (72% versus 65%) and nausea/vomiting (36 % versus 12%). The combination DOX-CDDP provided a significantly higher response rate than single agent DOX (P <0.001). Thirty-nine patients (43%) responded on DOX-CDDP [13 complete responses (CRs) and 26 partial responses (PRs)], versus 15 patients (17%) on DOX alone (8 CR and 7 PR). The median overall survival (OS) was 9 months in the DOX-CDDP arm versus 7 months in the DOX alone arm (Wilcoxon P = 0.0654). Regression analysis showed that WHO performance status was statistically significant as a prognostic factor for survival, and stratifying for this factor, treatment effect reaches significance (hazard ratio = 1.46, 95% confidence interval 1.05-2.03, P = 0.024). Conclusions: In comparison to single agent DOX, the combination of DOX-CDDP results in higher but acceptable toxicity. The response rate produced is significantly higher, and a modest survival benefit is achieved with this combination regimen, especially in patients with a good performance status

7. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.

Author

Arits AH, Stoot JE, Botterweck AA, Roumen FJ, and Voogd AC

Subjects
Adult, Aged, Aged, 80 and over, Ascites pathology, CA-125 Antigen analysis, Female, Humans, Middle Aged, Neoplasm Staging, Neoplasm, Residual, Neoplasms, Glandular and Epithelial blood, Neoplasms, Glandular and Epithelial pathology, Ovarian Neoplasms blood, Ovarian Neoplasms pathology, Ovariectomy rehabilitation, Preoperative Care, Prognosis, Retrospective Studies, Sensitivity and Specificity, Treatment Outcome, CA-125 Antigen blood, Neoplasms, Glandular and Epithelial diagnosis, Neoplasms, Glandular and Epithelial surgery, Ovarian Neoplasms diagnosis, Ovarian Neoplasms surgery, Ovariectomy methods
Abstract

The objective is to assess the ability of preoperative serum CA125 levels to identify patients at high risk of suboptimal cytoreductive surgery for epithelial ovarian cancer (EOC). One hundred and thirty-two women diagnosed with EOC between 1998 and 2004, who had serum CA125 levels measured preoperatively and received primary cytoreductive surgery, were retrospectively evaluated. The value of CA125 and patient and disease characteristics to predict suboptimal cytoreduction were determined, and a prognostic scoring system, based on statistically significant variables, was created. Optimal cytoreduction was achieved in 42.7% of the women with FIGO stage III/IV EOC. The optimal cutoff point of preoperative CA125 to predict surgical outcome in this group was 330 U/mL (sensitivity 80.0%; specificity 41.5%). The area under the receiver-operating characteristic curve (AUC) for preoperative CA125 predicting suboptimal surgery in FIGO stage III/IV was 0.576 (P = 0.617). Preoperative radiologic amount of ascites and weight loss (ie, >or=10% in the last 6 months before diagnosis) were independent prognostic factors for suboptimal cytoreduction, showing an AUC of 0.76 (P < 0.001) in women with FIGO stage III/IV. A prognostic scoring system showed that the chance of suboptimal surgery was 84.6% in FIGO stage III/IV when both these factors are present preoperatively. The role of CA125 levels predicting suboptimal cytoreduction seems questionable. Instead, women with considerable weight loss and a gross amount of ascites have a higher risk of suboptimal cytoreduction. These patients may be candidates for neoadjuvant chemotherapy.

Published
2008
Full Text
View/download PDF

8. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.

Author

van Wijk FH, Aapro MS, Bolis G, Chevallier B, van der Burg ME, Poveda A, de Oliveira CF, Tumolo S, Scotto di Palumbo V, Piccart M, Franchi M, Zanaboni F, Lacave AJ, Fontanelli R, Favalli G, Zola P, Guastalla JP, Rosso R, Marth C, Nooij M, Presti M, Scarabelli C, Splinter TA, Ploch E, Beex LV, ten Bokkel Huinink W, Forni M, Melpignano M, Blake P, Kerbrat P, Mendiola C, Cervantes A, Goupil A, Harper PG, Madronal C, Namer M, Scarfone G, Stoot JE, Teodorovic I, Coens C, Vergote I, and Vermorken JB

Subjects
Adenocarcinoma pathology, Adult, Aged, Antibiotics, Antineoplastic administration & dosage, Antibiotics, Antineoplastic adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cisplatin administration & dosage, Doxorubicin administration & dosage, Doxorubicin adverse effects, Endometrial Neoplasms pathology, Female, Health Status, Humans, Infusions, Intravenous, Male, Middle Aged, Prognosis, Survival Analysis, Treatment Outcome, Adenocarcinoma drug therapy, Antibiotics, Antineoplastic therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Doxorubicin therapeutic use, Endometrial Neoplasms drug therapy
Abstract

Background: Combination chemotherapy yields better response rates which do not always lead to a survival advantage. The aim of this study was to investigate whether the reported differences in the efficacy and toxicity of monotherapy with doxorubicin (DOX) versus combination therapy with cisplatin (CDDP) in endometrial adenocarcinoma lead to significant advantage in favour of the combination., Patients and Methods: Eligible patients had histologically-proven advanced and/or recurrent endometrial adenocarcinoma and were chemo-naïve. Treatment consisted of either DOX 60 mg/m(2) alone or CDDP 50 mg/m2 added to DOX 60 mg/m2, every 4 weeks., Results: A total of 177 patients were entered and median follow-up is 7.1 years. The combination DOX-CDDP was more toxic than DOX alone. Haematological toxicity consisted mainly of white blood cell toxicity grade 3 and 4 (55% versus 30%). Non-haematological toxicity consisted mainly of grade 3 and 4 alopecia (72% versus 65%) and nausea/vomiting (36 % versus 12%). The combination DOX-CDDP provided a significantly higher response rate than single agent DOX (P <0.001). Thirty-nine patients (43%) responded on DOX-CDDP [13 complete responses (CRs) and 26 partial responses (PRs)], versus 15 patients (17%) on DOX alone (8 CR and 7 PR). The median overall survival (OS) was 9 months in the DOX-CDDP arm versus 7 months in the DOX alone arm (Wilcoxon P = 0.0654). Regression analysis showed that WHO performance status was statistically significant as a prognostic factor for survival, and stratifying for this factor, treatment effect reaches significance (hazard ratio = 1.46, 95% confidence interval 1.05-2.03, P = 0.024)., Conclusions: In comparison to single agent DOX, the combination of DOX-CDDP results in higher but acceptable toxicity. The response rate produced is significantly higher, and a modest survival benefit is achieved with this combination regimen, especially in patients with a good performance status.

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results